Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering
Липидные наночастицы превосходят электропорацию при конструировании CAR-T-клеток на основе мРНК
2023-10-18
SCID: 54.1/44fvpnt8
Discuss with AI
CAR T cell engineeringchimeric antigen receptorselectroporationlipid nanoparticlesmRNA delivery
Figures from the paper
Abstract (AI)
Engineered T cells expressing chimeric antigen receptors (CARs) have been proven as efficacious therapies against selected hematological malignancies. However, the approved CAR T cell therapeutics strictly rely on viral transduction, a time- and cost-intensive procedure with possible safety issues. Therefore, the direct transfer of in vitro transcribed CAR-mRNA into T cells is pursued as a promising strategy for CAR T cell engineering. Electroporation (EP) is currently used as mRNA delivery method for the generation of CAR T cells in clinical trials but achieving only poor anti-tumor responses. Here, lipid nanoparticles (LNPs) were examined for ex vivo CAR-mRNA delivery and compared with EP. LNP-CAR T cells showed a significantly prolonged efficacy in vitro in comparison with EP-CAR T cells as a result of extended CAR-mRNA persistence and CAR expression, attributed to a different delivery mechanism with less cytotoxicity and slower CAR T cell proliferation. Moreover, CAR expression and in vitro functionality of mRNA-LNP-derived CAR T cells were comparable to stably transduced CAR T cells but were less exhausted. These results show that LNPs outperform EP and underline the great potential of mRNA-LNP delivery for ex vivo CAR T cell modification as next-generation transient approach for clinical studies.
Key Findings
1
CAR expression and in vitro functionality of LNP-derived CAR T cells were comparable to stably transduced CAR T cells, while exhaustion was reduced.
2
LNP delivery was associated with lower cytotoxicity and slower CAR T-cell proliferation than electroporation.
3
LNP-derived CAR T cells showed significantly longer in vitro efficacy than electroporated cells because of greater CAR-mRNA persistence and prolonged CAR expression.
4
Lipid nanoparticles enabled ex vivo delivery of CAR mRNA into T cells and outperformed electroporation in CAR T-cell engineering.
5
The findings support mRNA-LNP delivery as a promising transient, nonviral approach for clinical CAR T-cell modification.
Research Object
ex vivo CAR T cells engineered by delivery of in vitro-transcribed CAR mRNA using lipid nanoparticles or electroporation
Research Subject
Comparative CAR-mRNA delivery performance, including CAR-mRNA persistence, CAR expression, anti-tumor efficacy, cytotoxicity, proliferation, functionality, and exhaustion
Publication Details
Publication Date
2023-10-18
Journal
Publisher
ISSN
Cited by
128
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest